Immuron Ltd (IMRN) stock
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.90+0.05 (+5.86%)
Close on Nov 20, 2026Market cap $7.26MP/E –Yield –
Immuron gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2026 it was A$4.98M, up 4.4% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is A$4.98M in fiscal 2026.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$4.98M | +4.4% |
| FY2025 | Jun 30, 2025 | A$4.77M | +42.8% |
| FY2024 | Jun 30, 2024 | A$3.34M | +154.9% |
| FY2023 | Jun 30, 2023 | A$1.31M | +150.1% |
| FY2022 | Jun 30, 2022 | A$523.50K | +452.8% |
| FY2021 | Jun 30, 2021 | A$94.71K | -94.8% |
| FY2020 | Jun 30, 2020 | A$1.83M | +6.4% |
| FY2019 | Jun 30, 2019 | A$1.72M | +20.8% |
| FY2018 | Jun 30, 2018 | A$1.42M | +34.5% |
| FY2017 | Jun 30, 2017 | A$1.06M | +51.3% |
| FY2016 | Jun 30, 2016 | A$699.64K | – |
See a number that looks wrong?